John Lepore

Bio:

John Lepore, M.D., is CEO and President of ProFound Therapeutics and CEO-Partner at Flagship Pioneering, where he is leading a new era of drug discovery by harnessing the expanded proteome to build a pipeline of first-in-class medicines. A physician-scientist and accomplished pharma executive, he joined ProFound following a 17-year career at GSK, where he was most recently SVP, Head of Research, leading a global team driving a renewed focus on immunology and human genetics across target discovery and validation, modality platforms, drug discovery, and clinical translation. He also chaired GSK’s Research Review and Investment Boards, guiding capital allocation and R&D strategy. Before joining the biopharma industry, Dr. Lepore was a faculty cardiologist and research investigator at the University of Pennsylvania, where his lab investigated the transcription regulation of cardiovascular development. He currently serves on the boards of ProFound Therapeutics, KSQ Therapeutics, and the Innovation Growth Board of Mass General Brigham and was formerly on the board of BIO and ViiV Healthcare.

Dr. Lepore received his B.S. in Biology from the University of Scranton and his M.D. from Harvard Medical School, after which he completed his residency and post-doctoral training at Massachusetts General Hospital and the Harvard School of Public Health.